TY - JOUR
T1 - Long term results of interferon treatment in hairy cell leukemia italian cooperative group of hairy cell leukemia (ICGHCL)
AU - Capnist, Giovanni
AU - Federico, Massimo
AU - Chisesi, Teodoro
AU - Resegotti, Luigi
AU - Lamparelli, Teresa
AU - Fabris, Piero
AU - Rossi, Giuseppe
AU - Invernizzi, Rosangela
AU - Guarnaccia, Clara
AU - Leoni, Pietro
AU - Lauria, Franco
AU - Pagnucco, Guido
AU - Frassoldati, Antonio
AU - Damask, Eugenio
PY - 1994
Y1 - 1994
N2 - Eighty nine of 104 patients with hairy cell leukemia (HCL), enrolled between 1985 and 1987 in a multicenter prospective study on human lymphoblastoid IFN alpha-n1, were evaluable for long-term follow-up. The induction treatment, 3 MU/mq daily for a median of 5.7 months, produced a response of 93% complete + partial response (CR + PR) = 80% minor (MR) = 13% Neither prior splenectomy nor pre-treatment variables were associated with the rate of response to IFN. However maintenance treatment of 3 MU/mq weekly given randomly had a highly significant effect on failure free survival (FFS). Of the 43 patients who relapsed, 31/36 (86% obtained a new response with IFN. No differences in FFS were recorded between first and second response. At the third induction 7/11 patients were treated again with IFN, 4/7 obtaining some response, but the FFS was significantly worse. The overall survival is still 85% We conclude that (1) IFN should be used as chronic uninterrupted treatment for HCL, (2) reduced dosage is sufficient to prolong the disease free status and (3) continuous lymphoblastoid IFN administration seems not to be associated with the development of resistance to retreatment.
AB - Eighty nine of 104 patients with hairy cell leukemia (HCL), enrolled between 1985 and 1987 in a multicenter prospective study on human lymphoblastoid IFN alpha-n1, were evaluable for long-term follow-up. The induction treatment, 3 MU/mq daily for a median of 5.7 months, produced a response of 93% complete + partial response (CR + PR) = 80% minor (MR) = 13% Neither prior splenectomy nor pre-treatment variables were associated with the rate of response to IFN. However maintenance treatment of 3 MU/mq weekly given randomly had a highly significant effect on failure free survival (FFS). Of the 43 patients who relapsed, 31/36 (86% obtained a new response with IFN. No differences in FFS were recorded between first and second response. At the third induction 7/11 patients were treated again with IFN, 4/7 obtaining some response, but the FFS was significantly worse. The overall survival is still 85% We conclude that (1) IFN should be used as chronic uninterrupted treatment for HCL, (2) reduced dosage is sufficient to prolong the disease free status and (3) continuous lymphoblastoid IFN administration seems not to be associated with the development of resistance to retreatment.
KW - Hairy cell leukemia
KW - Interferon
UR - http://www.scopus.com/inward/record.url?scp=0027978250&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027978250&partnerID=8YFLogxK
U2 - 10.3109/10428199409049704
DO - 10.3109/10428199409049704
M3 - Article
C2 - 7812205
AN - SCOPUS:0027978250
VL - 14
SP - 457
EP - 464
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 5-6
ER -